Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - trastuzumab 120 mg/ml - solution for injection - 600 mg/5ml - active: trastuzumab 120 mg/ml excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 trehalose dihydrate water for injection - herceptin sc is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; or b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trastuzumab, quantity: 600 mg - injection, solution - excipient ingredients: vorhyaluronidase alfa; histidine hydrochloride monohydrate; histidine; trehalose dihydrate; methionine; polysorbate 20; water for injections - early breast cancer: herceptin sc is indicated for the treatment of her2-positive localised breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,locally advanced breast cancer: herceptin sc is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant herceptin.,metastatic breast cancer: herceptin sc is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,- as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,- in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,- in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.

Kanada - Kiingereza - Health Canada

pfizer canada ulc - dinoprostone - gel - 0.5mg - dinoprostone 0.5mg - oxytocics

Kanada - Kiingereza - Health Canada

pfizer canada ulc - carboprost (carboprost tromethamine) - solution - 250mcg - carboprost (carboprost tromethamine) 250mcg - oxytocics

Kanada - Kiingereza - Health Canada

advanced dosage forms inc. - alprostadil - solution - 500mcg - alprostadil 500mcg - miscellaneous vasodilatating agents

Kanada - Kiingereza - Health Canada

mylan pharmaceuticals ulc - clindamycin (clindamycin phosphate) - solution - 150mg - clindamycin (clindamycin phosphate) 150mg - lincomycins

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trastuzumab, quantity: 60 mg - injection, powder for - excipient ingredients: histidine hydrochloride monohydrate; polysorbate 20; trehalose dihydrate; histidine - early breast cancer. herceptin is indicated for the treatment of patients with her2 positive localised breast cancer following surgery, and in assocoation with chemotherapy and, if applicable, radiotherapy. locally advanced breast cancer.herceptin is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant herceptin. metastatic breast cancer. herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease, b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer. advanced gastric cancer. herceptin is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - trastuzumab, quantity: 150 mg - injection, powder for - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20 - early breast cancer. herceptin is indicated for the treatment of patients with her2 positive localised breast cancer following surgery, and in assocoation with chemotherapy and, if applicable, radiotherapy. locally advanced breast cancer.herceptin is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant herceptin. metastatic breast cancer. herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease, b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer. advanced gastric cancer. herceptin is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

biocon sdn bhd - trastuzumab -

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

biocon sdn bhd - trastuzumab -